Determining Potential Mechanisms of Worse Outcomes in Black HCM Patients
确定黑人 HCM 患者出现更糟糕结果的潜在机制
基本信息
- 批准号:10717764
- 负责人:
- 金额:$ 77.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-10 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAgeArrhythmiaBiological AssayBiological MarkersBiological ModelsBlack PopulationsBlack raceCardiacCardiac MyocytesCessation of lifeClinicalClinical DataDataDevelopmentDiagnosisDiseaseDisparityDisparity in diagnosisEchocardiographyElectrocardiogramElectrophysiology (science)ExhibitsFibrosisFunctional disorderGeneticGenotypeGoalsHealth StatusHeartHeart DiseasesHeart failureHeritabilityHospitalizationHumanHypertensionHypertrophic CardiomyopathyHypertrophyImplantable DefibrillatorsIn VitroIndividualInterventionLeft Ventricular Ejection FractionLeft Ventricular HypertrophyMechanicsMedical GeneticsModelingMolecularMutationMyocardiumOutcomePathogenicityPathway interactionsPatient CarePatient-Focused OutcomesPatientsPhenotypePhysiciansPhysiologyPlasmaPopulationPredispositionProteomicsQuality of lifeResearch PersonnelResistanceRestRiskRisk FactorsSarcomeresTissue EngineeringVariantadverse outcomeblack patientcardiac tissue engineeringcardiogenesiscohortcourse developmentgenetic testinggenetic variantgenome editingimprovedin vitro Modelinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinduced pluripotent stem cell technologyinsightminiaturizemortalitymouse modelnovelpeerpressureracial disparityresearch clinical testingrisk stratificationsudden cardiac deathtoolvariant of interestvariant of unknown significanceyoung adult
项目摘要
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disease. Individuals with HCM have
adverse clinical outcomes, including heart failure, arrhythmias, and sudden cardiac death (SCD) It is estimated
.
that, in the U.S., 6 out of 7 individuals with HCM are unaware of their diagnosis. There are recognized racial
disparities in the diagnosis of HCM. While Black individuals have been observed to have more clinical and ECG
signs that should promote consideration of the diagnosis of HCM, HCM is underdiagnosed in Black patients.
Furthermore, even once diagnosed, there are well-recognized disparities between Black and White patients with
HCM; Black patients have lower rates of referral to HCM Centers, referral for genetic testing, referral for SCD
risk stratification, and referral for interventions such as septal reduction therapy and implantable cardioverter-
defibrillator (ICD) placement. The lower rates of referral are in direct opposition to the data that shows that,
compared to Whites, Black individuals with HCM have approximately 2-fold the risk of SCD and development of
class III or IV (moderate or severe) heart failure. There are several potential contributors to these racial
disparities. HCM is typically diagnosed using routine echocardiography and clinical genetic testing is used to
help diagnose ambiguous cases. Black individuals with HCM are more likely to have ambiguous presentations
and clinical testing is less useful as, compared to Whites, Black patients with HCM are ~40% less likely to have
a pathogenic or likely pathogenic (P/LP) sarcomeric variant identified and more than 40% more likely to have
variants of uncertain significance (VUS). Furthermore, hypertension (HTN) is more prevalent in Black individuals
and physicians may attribute the patient’s left ventricular hypertrophy to HTN and not consider HCM.
In addition,
recent evidence suggests that HTN may be an environmental modifier /”trigger” of worse disease in patients with
HCM. Dr. Huebsch, Co-investigator on this proposal, created an in vitro micro-heart (μHM) model system from
cardiomyocytes derived from human induced pluripotent stem cells (iPSC) harboring single sarcomere mutations
and has used this model system to help tease apart the contributions of afterload and genetics in HCM. We
hypothesize that the presence of (1) multiple sarcomeric variants and (2) HTN contribute to the worse outcomes
observed in Black HCM patients. AIM 1. To assess adverse outcomes in Black HCM patients with (vs without)
(A) more than one variant (i.e. 2 P/LP variants or 1 P/LP variant + 1 or more VUS) and (B) HTN, in 2 real-world
U.S. cohorts of HCM patients. An exploratory analysis using Somascan assays to identify novel plasma
proteomic biomarkers of adverse outcomes will also be performed. AIM 2. To characterize the effects of multiple
variants on cardiac physiology and fibrosis in our novel in vitro μHM model subjected to increased afterload.
Combining patient clinical data with powerful in vitro tools of iPSC technology, genome editing and tissue
engineering, will allow us to gain important insights and understanding of potential triggers and mechanisms
contributing to worse outcomes in Black HCM patients.
肥厚型心肌病(HCM)是最常见的遗传性心脏病。患有肥厚型心肌炎的人有
据估计,不良的临床后果包括心力衰竭、心律失常和心脏性猝死(SCD)
。
在美国,每7个人中就有6个人不知道自己的诊断结果。有公认的种族
肥厚型心肌炎诊断上的差异。而黑人个体被观察到有更多的临床和心电图
应促进考虑诊断为肥厚型心肌病的体征,在黑人患者中,肥厚型心肌病被低估了。
此外,即使一旦确诊,黑人和白人患者之间也存在着公认的差异
HCM;黑人患者转诊到HCM中心、转诊进行基因检测、转诊为SCD的比率较低
风险分层,并转诊进行介入治疗,如间隔缩小治疗和植入性心脏复律-
放置除颤器(ICD)。较低的转诊率与数据直接相反,数据显示,
与白人相比,患有肥厚性心肌病的黑人患上SCD和发展为
III级或IV级(中度或严重)心力衰竭。有几个潜在的因素导致了这些种族
差距。肥厚性心肌病通常使用常规超声心动图诊断,临床基因检测用于
帮助诊断不明确的案例。患有肥胖症的黑人更有可能有模棱两可的陈述
临床测试没有那么有用,因为与白人相比,患有肥厚性心肌炎的黑人患者患肥厚性心肌炎的可能性低约40%。
发现一种致病或可能致病的(P/LP)肉瘤变异体,有40%以上的可能性
不确定意义的变种(VU)。此外,高血压(HTN)在黑人中更普遍
医生可能会将患者的左心室肥厚归因于HTN,而不考虑肥厚性心肌病。
此外,
最近的证据表明,HTN可能是一种环境修饰物/更严重疾病的触发因素
胡志明市。Huebsch博士是这项提议的联合研究员,他创建了一个体外微型心脏(μHM)模型系统,该模型系统由
含有单一肌节突变的人诱导多能干细胞(IPSC)来源的心肌细胞
并使用该模型系统来帮助梳理后负荷和遗传学在HCM中的作用。我们
假设(1)多种肉瘤变异体和(2)HTN的存在会导致更差的结果
在黑人肥厚型心肌病患者中观察到。目的1.评估黑人肥厚型心肌病患者的不良结局
(A)一个以上的变体(即2个P/LP变体或1个P/LP变体+1个或更多VU)和(B)HTN,在2个真实世界中
美国肥厚型心肌炎患者队列。用Somascan分析鉴定新血浆的探索性分析
不良结果的蛋白质组生物标记物也将被执行。目标2.描述多个因素的影响
在我们的新型体外μHM模型中,心脏生理学和纤维化的变异受到增加的后负荷的影响。
将患者临床数据与IPSC技术、基因组编辑和组织等强大的体外工具相结合
工程学,将使我们能够获得对潜在触发因素和机制的重要见解和理解
导致黑人肥厚型心肌炎患者预后更差。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHARON CRESCI其他文献
SHARON CRESCI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHARON CRESCI', 18)}}的其他基金
PREDICTION OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF): A NEW PLASMA BIOMARKER
保留射血分数 (HFPEF) 的心力衰竭结果预测:一种新的血浆生物标志物
- 批准号:
9810249 - 财政年份:2019
- 资助金额:
$ 77.75万 - 项目类别:
Genomic variants associated with angina and health status outcome after MI
与心绞痛和心肌梗死后健康状况结果相关的基因组变异
- 批准号:
9197213 - 财政年份:2011
- 资助金额:
$ 77.75万 - 项目类别:
Genomic variants associated with angina and health status outcome after MI
与心绞痛和心肌梗死后健康状况结果相关的基因组变异
- 批准号:
8521389 - 财政年份:2011
- 资助金额:
$ 77.75万 - 项目类别:
Genomic variants associated with angina and health status outcome after MI
与心绞痛和心肌梗死后健康状况结果相关的基因组变异
- 批准号:
8258932 - 财政年份:2011
- 资助金额:
$ 77.75万 - 项目类别:
Genomic variants associated with angina and health status outcome after MI
与心绞痛和心肌梗死后健康状况结果相关的基因组变异
- 批准号:
8339338 - 财政年份:2011
- 资助金额:
$ 77.75万 - 项目类别:
Genomic variants associated with angina and health status outcome after MI
与心绞痛和心肌梗死后健康状况结果相关的基因组变异
- 批准号:
8818197 - 财政年份:2011
- 资助金额:
$ 77.75万 - 项目类别:
Association of PPAR-pathway gene polymorphisms with diabetic outcomes in BARI 2D
BARI 2D 中 PPAR 通路基因多态性与糖尿病结局的关联
- 批准号:
7297134 - 财政年份:2007
- 资助金额:
$ 77.75万 - 项目类别:
Association of PPAR-pathway gene polymorphisms with diabetic outcomes in BARI 2D
BARI 2D 中 PPAR 通路基因多态性与糖尿病结局的关联
- 批准号:
7481145 - 财政年份:2007
- 资助金额:
$ 77.75万 - 项目类别:
TRANSCRIPTIONAL REGULATION OF MCAD GENE EXPRESSION
MCAD 基因表达的转录调控
- 批准号:
2214184 - 财政年份:1995
- 资助金额:
$ 77.75万 - 项目类别:
TRANSCRIPTIONAL REGULATION OF MCAD GENE EXPRESSION
MCAD 基因表达的转录调控
- 批准号:
2214183 - 财政年份:1995
- 资助金额:
$ 77.75万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Continuing Grant
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 77.75万 - 项目类别:
Research Grant